Ipsen S.A. (LON: 0MH6)

Market Cap	8.22B
Revenue (ttm)	2.91B
Net Income (ttm)	577.53M
Shares Out	n/a
EPS (ttm)	6.91
PE Ratio	14.23
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	May 30, 2024

Volume	2,698
Average Volume	62,458
Open	122.35
Previous Close	123.00
Day's Range	119.90 - 122.40
52-Week Range	82.42 - 104.61
Beta	0.58
RSI	54.82
Earnings Date	Feb 13, 2025

About Ipsen

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical t...

• Industry: Pharmaceutical Preparations
• Founded: 1929
• Employees: 5,325
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0MH6

Financial Performance

In 2023, Ipsen's revenue was 3.31 billion, an increase of 4.75% compared to the previous year's 3.16 billion. Earnings were 644.40 million, a decrease of -0.65%.

Financial numbers in EUR